Moderna, Inc. - Common Stock (MRNA)
27.14
-0.58 (-2.09%)
NASDAQ · Last Trade: Oct 16th, 5:26 PM EDT
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.
Via The Motley Fool · October 15, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · October 15, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · October 15, 2025
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations legislation for the 2026 fiscal year. This eleventh government shutdown in U.S. history is sending ripples of
Via MarketMinute · October 14, 2025
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.
Via Benzinga · October 14, 2025
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Via The Motley Fool · October 14, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study.
Via StockStory · October 13, 2025
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant melanoma patients.
Via Benzinga · October 13, 2025
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Via StockStory · October 13, 2025
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Via StockStory · October 10, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
Via Chartmill · October 8, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
Via MarketMinute · October 8, 2025
Washington D.C., October 8, 2025 – The U.S. federal government remains in the throes of a shutdown, now entering its second week, as lawmakers in Washington continue to grapple with a stalemate over federal funding for Fiscal Year 2026. This ongoing budgetary impasse, which commenced on October 1, 2025,
Via MarketMinute · October 8, 2025
As the United States government enters its second week of shutdown, a remarkable divergence is playing out on Wall Street. While political pundits grapple with congressional gridlock, the S&P 500 has soared to unprecedented heights, marking an extraordinary eighth consecutive day of gains as of October 7, 2025. This
Via MarketMinute · October 7, 2025
As of October 3, 2025, the United States federal government finds itself in the throes of a significant shutdown, marking the eleventh such occurrence in modern American history and the third under President Donald Trump. The funding lapse, which began at 12:01 a.m. EDT on October 1, 2025,
Via MarketMinute · October 3, 2025
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
Via MarketMinute · October 2, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via Chartmill · October 2, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via Benzinga · October 1, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · October 1, 2025
Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.
Via Benzinga · October 1, 2025
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · October 1, 2025
These biotechs should benefit from their innovative ways.
Via The Motley Fool · September 30, 2025
Washington D.C. – Global financial markets are once again gripped by uncertainty as a potential United States government shutdown looms, threatening to disrupt critical economic data releases and send ripples through currency markets. As of late September 2025, the prospect of an impasse in Washington over funding bills has heightened
Via MarketMinute · September 29, 2025